Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Abstract
Homologous recombination (HR) deficiency (HRD) is one of the key determinants of PARP inhibitor response in ovarian cancer, and its accurate detection in tumor biopsies is expected to improve the efficacy of this therapy. Because HRD induces a wide array of genomic aberrations, mutational signatures may serve as a companion diagnostic to identify PARP inhibitor–responsive cases.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 11, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-0981
Entities
People
- Aurel Prosz
- Judit Börcsök
- Maj K. Kjeldsen
- Mansoor R. Mirza
- Miklos Diossy
- Nanna Cornelius
- Zoltán Szállási
- Zsófia Sztupinszki
Organizations
- Copenhagen University Hospital
- Hungarian Academy of Sciences
- Novo Nordisk Fonden
- The Breast Cancer Research Foundation
- United States Department of Defense
- Velux Foundation